Biomanufacturer Antheia bolsters commercial drug ingredients prospects with TAPI alliance

After several notable moves to grow the reach of its biomanufacturing platform in recent months, Antheia is linking arms with a pharmaceutical ingredient juggernaut in this field.
Antheia and TAPI Partner to Advance Global Commercialization Strategy for Critical Pharmaceutical Ingredients

This partnership will allow Antheia to harness TAPI’s next-generation fermentation capabilities and manufacturing facilities in Europe, aimed at further commercializing its pipeline of biosynthetic key starting materials (KSMs) and active pharmaceutical ingredients (APIs).
Antheia and TAPI Partner to Advance Global Commercialization Strategy for Critical Pharmaceutical Ingredients
New partnership will enable Antheia to increase scale and accelerate time to market for future product launches Menlo Park, Calif. and Parsippany, N.J. – November 20, 2025 – Antheia, the pharmaceutical ingredient manufacturer transforming essential medicine supply chains, and TAPI – Technology and API Services, today announced a strategic partnership. Antheia will leverage TAPI’s next-generation fermentation capabilities and manufacturing facilities in Europe to further commercialize its pipeline of biosynthetic key starting […]